Advertisement

Advertisement

© 2025 Mapquest Holdings LLC
© HERE
Privacy
Legal
About Our Ads
Do Not Sell or Share my Personal Data
HotelsFoodShoppingCoffeeGroceryGas

Marker Therapeutics, Inc

+1 (713) 400-6400
Website

Advertisement

Advertisement

2450 Holcombe Blvd Ste Bcm-A
Houston, TX 77021
+1 (713) 400-6400
https://markertherapeutics.com

Marker Therapeutics, Inc. is a Houston-based biotechnology company focused on the development and commercialization of innovative T cell-based immunotherapies for patients with various blood and solid tumor cancers. Their groundbreaking MultiTAA technology utilizes non-genetically engineered T cells that can recognize and eliminate multiple tumor targets, aiming to create more precise and safer treatments with broad and long-lasting anti-cancer effects.

With a commitment to advancing the field of immunotherapy, Marker Therapeutics aims to provide patients with next-generation therapies that offer improved outcomes and quality of life. Through their cutting-edge research and development efforts, they strive to revolutionize cancer treatment and make a significant impact in the fight against cancer.

Generated from the website

Also at this address

Icellkealex Therapeutics LLC

Suarez-Almazor, Maria E MD

Giardino, Angelo, P, MD

Polyvascular Corp

Own this business?
See a problem?

You might also like

Sizes, Drugs and drug proprietaries

Salarius Pharmaceuticals, Inc

Iterion Therapeutics is a clinical-stage biopharmaceutical company based in Houston, TX, dedicated to revolutionizing healthcare through innovative drug discovery. Their lead product, tegavivint, is a first-in-class small molecule inhibitor that targets Transducin Beta-like Protein 1 (TBL1), a key component of the Wnt beta-catenin signaling pathway implicated in various types of cancers. By binding to TBL1 and displacing beta-catenin, tegavivint inhibits oncogenic gene expression, offering a promising approach to treating cancer. Iterion Therapeutics has already demonstrated the safety, pharmacodynamic effects, and clinical activity of tegavivint in a completed Phase 1 clinical trial. They are currently enrolling patients for a company-sponsored clinical trial in hepatocellular carcinoma, a cancer type with a high prevalence of Wnt beta-catenin mutations and significant unmet clinical needs. Additionally, Iterion has established collaborative relationships with leading institutions to further investigate tegavivint's potential in complementary investigator-sponsored trials.Generated from the website

Doseme LLC

DoseMe LLC is a leading provider of Bayesian dosing software, offering the world's first and largest Bayesian dosing platform designed for clinical practice. Their intuitive dosing platform, DoseMeRx, simplifies the implementation of Bayesian dosing, allowing healthcare professionals to spend more time on patients and less on calculations. With 24/7 support from real people, DoseMeRx ensures that customers receive the best-in-class customer service. Trusted worldwide, DoseMeRx is clinically proven to significantly improve patient outcomes and lower costs, making it the go-to choice for clinical pharmacists. With a diverse range of drug models across various therapeutic areas, including vancomycin, infectious disease, oncology, and pediatrics, DoseMeRx offers a comprehensive solution for therapeutic drug monitoring. As the only HITRUST CSF certified Bayesian dosing platform, DoseMeRx prioritizes patient data security and integrity, providing peace of mind to healthcare providers. By standardizing workflows and optimizing therapeutic drug monitoring programs, DoseMeRx helps healthcare systems achieve continuity of care and simplify AUC compliance workflows. With numerous success stories from satisfied customers, DoseMeRx has revolutionized pharmacokinetic services and improved patient care in institutions worldwide.Generated from the website

Kiromic BioPharma, Inc

Kiromic BioPharma, Inc is a biopharmaceutical company based in Houston, Texas, focusing on the development of immunotherapy drugs for cancer treatment. The company aims to address the percentage of cancer deaths in the US that could potentially be treated with their innovative immunotherapy drugs. Generated from their website's infomation
United States›Texas›Houston›Marker Therapeutics, Inc

Partial Data by Infogroup (c) 2025. All rights reserved.

Advertisement

Advertisement

  • Get directions
  • MapQuest Travel
  • Route Planner
  • Print your map
  • Get help
  • Search the web
  • Send feedback
Learn more about our mobile apps.
  • Android app Google Play
  • Download on the App Store
  • Download on the Amazon Appstore
  • Enterprise solutions
  • Claim your business
  • Developer resources
  • Jobs
  • Advertise with us
  • Terms of use
  • Privacy policy
  • Data and licenses
  • About our ads
  • Do not sell